Diabeloop
- Company typePrivate
- Founded2015
- HeadquartersGrenoble, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Diabeloop firmographics
Firmographics- Name
- Diabeloop
- Legal name
- Diabeloop SA
- Website
- https://diabeloop.fr
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Diabeloop industry classification
Industry- Product category
- Automated Insulin Delivery Systems
- NAICS
- Custom Computer Programming Services (541511)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industries
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Diabetes (General) (HLAKADAA)
Keywords
Where Diabeloop is headquartered
LocationHeadquarters
- HQ city
- Grenoble
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Diabeloop business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure
Revenue model
- Medical Device Sales: Diabeloop sells its DBLG1 medical device systems (pumps, terminals, and associated components) as Class IIb/III medical devices in European markets. Components carry a 4-year warranty.
- Consumables and Ongoing Supply: Ongoing sales of consumables including sensors, infusion sets, and related supplies for the continuous glucose monitoring and insulin pump components of the system.
- Algorithm Licensing: Diabeloop licenses its DBLG2 automated insulin delivery algorithm to third-party insulin pump manufacturers for integration into their devices (e.g., Sequel Med Tech's twiist pump, ViCentra's Kaleido pump). Revenue is derived from technology licensing and integration agreements with OEM partners.
- Software Services (YourLoops): YourLoops is a CE-marked data visualization and monitoring platform for people with diabetes and their healthcare providers, generating ongoing software service revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | DBLG1 System with dedicated terminal (DH22 or MobiGo+) |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Diabeloop product offering
Product offeringCore offering
Diabeloop develops and commercializes AI-driven automated insulin delivery (AID) systems for type 1 diabetes management. Its flagship products DBLG1 and DBLG2 use a self-learning algorithm that processes continuous glucose monitoring data every 5 minutes to automatically calculate and adjust insulin dosing, functioning as a hybrid closed-loop artificial pancreas. DBLG2 is delivered as a smartphone application integrated with Dexcom G7 CGM and partner insulin pumps, while DBLG1 uses a dedicated terminal. The company also offers the YourLoops data visualization platform and licenses its algorithm to insulin pump manufacturers.
Product overview
Diabeloop offers an integrated portfolio of automated insulin delivery (AID) systems for type 1 diabetes management. The core product is the DBLG2 system (latest generation) and its predecessor DBLG1, both featuring self-learning AI algorithms that automate insulin delivery based on real-time continuous glucose monitoring data. These systems integrate with third-party CGM sensors (Dexcom G6/G7) and insulin pumps (ViCentra Kaleido, Roche Accu-Chek Insight, Sequel twiist). The product ecosystem includes YourLoops, a CE-marked data visualization platform for patients and healthcare providers. DBL-hu addresses the pediatric and unstable diabetes segments. The company is transitioning from hardware-based terminals to a mobile-first software approach via smartphone applications.
Differentiator
Problem solved
Functional benefit
Products and services
- DBLG2 Automated Insulin Delivery System Second-generation automated insulin delivery system featuring a self-learning AI algorithm hosted directly on the patient's smartphone. Eliminates the need for a dedicated hardware terminal and integrates with Dexcom G7 CGM and compatible insulin pumps. Provides hybrid closed-loop insulin delivery with automatic adjustments every 5 minutes based on CGM data, with optional meal declaration and autonomous glycemic control.
- DBLG1 Automated Insulin Delivery System First-generation automated insulin delivery system using a dedicated terminal device (DH22 or MobiGo+) connected via Bluetooth to CGM sensors and insulin pumps. Class III medical device (DH22) or Class IIb (MobiGo+) with CE marking. The self-learning AI algorithm analyzes glucose data every 5 minutes and calculates optimal insulin dose based on each patient's personalized parameters.
- YourLoops Data Visualization Platform Class IIa CE-marked medical device platform for data visualization and remote monitoring. Enables people with diabetes and healthcare professionals to access health data, share information, and monitor treatment outcomes. Supports both patient self-management and clinician remote patient monitoring.
- DBL-hu (Highly Unstable Diabetes Solution) Automated insulin delivery solution specifically designed for type 1 diabetes patients with highly unstable or brittle diabetes. Addresses a more severe patient population requiring more advanced AID with specialized algorithms.
- Connected Insulin Pen Solutions Adaptation of Diabeloop's AI and connectivity technology for integration with connected insulin pen devices. Expands the company's portfolio beyond pump-based AID systems to include smart insulin pen delivery solutions for broader insulin therapy applications.
Quantifiable outcome
- Time in hypoglycemia: 2.04% in closed loop vs 7.06% in open loop in children aged 6-12 (Lancet Digital Health)
- +2 more outcomes
Companies that use Diabeloop
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Diabeloop technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature4 records
Diabeloop partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Sequel Med TechcoreSequel Med Tech and Diabeloop announced a collaboration to integrate Diabeloop's FDA-cleared DBLG2 algorithm into Sequel's twiist AID insulin pump — the first integration of Diabeloop's algorithm into a commercial insulin pump in the U.S. market. The twiist pump uses sound wave technology to measure microdoses of insulin. Product readiness expected end of 2026; initial U.S. launch planned for 2027, potentially followed by global expansion.
- Roche Diabetes CarecoreRoche and Diabeloop partnered to integrate the DBLG1 algorithm with Roche's Accu-Chek Insight insulin pump, advancing automated insulin delivery for type 1 diabetes. The companies co-hosted webinars and presented clinical evidence demonstrating improved diabetes management outcomes.
- ViCentracoreDiabeloop and ViCentra partnered to integrate DBLG2 with ViCentra's Kaleido insulin patch pump and Dexcom G7 CGM. ViCentra is establishing its own direct commercial entity in France, evolving the distribution model. Kaleido is described as the smallest, lightest, and most precise insulin patch pump in its category.
- Terumo CorporationcoreJoint development agreement with exclusive distribution rights for DBLG1 in the Japanese market. Terumo brings local regulatory expertise, distribution infrastructure, and market presence in Japan as a premier medical device company.
- SOOILminorSOOIL is listed among Diabeloop's international development partners, contributing to the company's interoperability strategy across multiple insulin pump manufacturers.
- BIOCORPminorBIOCORP partnered with Diabeloop on connected insulin pen solutions, expanding the company's technology portfolio beyond AID systems to include smart insulin delivery devices.
- EOFlowminorDiabeloop and EOFlow entered a co-development agreement to create a next-generation automated insulin delivery system using EOFlow's wearable insulin pump technology combined with Diabeloop's algorithm, accessible via a smartphone application.
- Novo NordiskminorDiabeloop announced a collaboration with Novo Nordisk in March 2023 to integrate its technology with Novo Nordisk's connected insulin pens, expanding Diabeloop's AID ecosystem to include smart insulin pen delivery.
- SanofiminorDiabeloop partnered with Sanofi for connected insulin pen solutions as part of its interoperability expansion strategy announced in April 2023.
Scale indicators8 records
Recent moves6 records
Expansion highlights8 records
Diabeloop competitors and assessment
Company assessmentDirect peers
- Tandem Diabetes Care: US-listed maker of the t:slim X2 insulin pump with Control-IQ hybrid closed-loop algorithm, directly competing with Diabeloop in the automated insulin delivery market for type 1 diabetes, with established US commercial reach.
- Medtronic (Diabetes division): Operates the MiniMed 780G AID system integrating its own proprietary algorithm with the Guardian CGM; the largest vertically integrated incumbent in AID and a direct competitor for the same patient population Diabeloop targets.
- Insulet Corporation: Maker of the Omnipod 5 tubeless patch pump with SmartAdjust AID algorithm; competes with Diabeloop's integrated approach and is an alternative AID option for type 1 diabetes patients globally.
- Beta Bionics: Developer of the iLet bionic pancreas AID system that uses an adaptive algorithm requiring no carb counting; an emerging AID competitor pursuing similar type 1 diabetes indications and recently FDA-cleared/commercialized.
- ViCentra: Maker of the Kaleido insulin patch pump, Diabeloop's integrated pump partner for DBLG2; an emerging patch-pump competitor increasingly pursuing its own commercial presence in France.
Emerging players
- CamDiab (CamAPS): University of Cambridge spin-out commercializing the CamAPS FX adaptive hybrid closed-loop algorithm integrated with multiple pumps and CGMs in Europe; closest direct algorithmic competitor to Diabeloop's DBLG1/DBLG2.
- Sequel Med Tech: Maker of the sound wave-based twiist AID pump that Diabeloop's DBLG2 algorithm is being integrated into for the 2027 US launch; both a key US commercial partner and a competitor for AID pump share.
Broad incumbents
- Dexcom: Leading CGM manufacturer and current Diabeloop CGM partner (G6/G7); owns its own algorithmic assets (acquired TypeZero) and represents both a critical partner and a strategic risk as it deepens AID capability internally.
- Roche Diabetes Care: Long-standing Diabeloop distribution and integration partner via the Accu-Chek Insight pump; a broader incumbent in BGM/CGM/pump that competes in the broader diabetes management landscape.
- Abbott Diabetes Care: Maker of the FreeStyle Libre CGM and ecosystem player; absorbed Bigfoot Biomedical and is a strategic competitor as it develops its own AID-capable ecosystem adjacent to Diabeloop's CGM partner Dexcom.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Diabeloop social profiles
Digital presenceDiabeloop compliance and trust
Trust signalCompliance6 records
Diabeloop financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diabeloop leadership team
Management profileNumber of profiles
Profiles6 records
Diabeloop funding detail
Funding detailFunding overview
Funding rounds6 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diabeloop M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diabeloop
What does Diabeloop do?
Diabeloop develops and commercializes AI-driven automated insulin delivery (AID) systems for type 1 diabetes management. Its flagship products DBLG1 and DBLG2 use a self-learning algorithm that processes continuous glucose monitoring data every 5 minutes to automatically calculate and adjust insulin dosing, functioning as a hybrid closed-loop artificial pancreas. DBLG2 is delivered as a smartphone application integrated with Dexcom G7 CGM and partner insulin pumps, while DBLG1 uses a dedicated terminal. The company also offers the YourLoops data visualization platform and licenses its algorithm to insulin pump manufacturers.
Is Diabeloop a public or private company?
Diabeloop is a private company. It is classified as venture growth investor backed and is currently operating.
When was Diabeloop founded?
Diabeloop was founded in 2015. It employs 51 to 100 people.
Where is Diabeloop based?
Diabeloop is headquartered in Grenoble, France, in the Europe region.
How does Diabeloop make money?
Four revenue lines are on record. Medical Device Sales are the primary driver. The others are consumables and Ongoing Supply, algorithm Licensing and software Services (YourLoops).
Who are Diabeloop's main competitors?
Direct peers on record are Tandem Diabetes Care, Medtronic (Diabetes division), Insulet Corporation, Beta Bionics and ViCentra. Emerging players are CamDiab (CamAPS) and Sequel Med Tech. Broad incumbents are Dexcom, Roche Diabetes Care and Abbott Diabetes Care.
Does Diabeloop have an API?
No public API is recorded for Diabeloop.
What industry is Diabeloop in?
Diabeloop's product category is Automated Insulin Delivery Systems. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 541511 and its SIC code is 7370.